Similar articles

• Response by Bagai et al to Letter Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention".

  Bagai A, Bhatt DL, Verma S, Mehta SR. Bagai A, et al. Circulation. 2016 Oct 11;134(15):e334-e335. doi: 10.1161/CIRCULATIONAHA.116.024526. Circulation. 2016. PMID: 27753619 No abstract available.
• Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?

  Calabrò P, Gragnano F, De Luca L. Calabrò P, et al. Am J Med. 2017 Nov;130(11):e515. doi: 10.1016/j.amjmed.2017.06.035. Am J Med. 2017. PMID: 29073976 No abstract available.
• Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.

  Bagai A, Bhatt DL, Eikelboom JW, Mancini GB, Cohen EA, Vijayaraghavan R, Cheema AN, Udell JA, Niznick J, Tanguay JF, Verma S, Mehta SR. Bagai A, et al. Circulation. 2016 May 24;133(21):2094-8. doi: 10.1161/CIRCULATIONAHA.115.021158. Circulation. 2016. PMID: 27217435 Review. No abstract available.
• How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?

  Li J, Yan G. Li J, et al. Int J Cardiol. 2018 Nov 15;271:28. doi: 10.1016/j.ijcard.2018.05.121. Int J Cardiol. 2018. PMID: 30223357 No abstract available.
• Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.

  Paravattil B, Elewa H. Paravattil B, et al. J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):347-355. doi: 10.1177/1074248416683048. Epub 2016 Dec 21. J Cardiovasc Pharmacol Ther. 2017. PMID: 28587584 Review.